Levofolic (Levoleucovorin Disodium)

Levoleucovorin disodium is a reduced folate that bypasses the dihydrofolate reductase step, directly entering the folate cycle as 5‑methyltetrahydrofolate. This restores nucleotide synthesis in cells affected by antifolate drugs and stabilizes the binding of 5‑fluorouracil metabolites to thymidylate synthase, thereby supporting DNA/RNA production and enhancing chemotherapeutic activity.

The dose of Levofolic is individualized and determined by the prescribing healthcare professional based on the specific clinical situation, such as the type of chemotherapy, patient weight, renal function, and treatment protocol. No standard dosing regimen is provided here.

Safety data for levoleucovorin disodium in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Levofolic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Levofolic (levoleucovorin) is a reduced folate, whereas standard folic acid requires enzymatic reduction before use. Levofolic provides immediate bioavailable folate, making it more effective for rapid rescue from methotrexate toxicity and for potentiating 5‑fluorouracil, while plain folic acid is less efficient in these settings.

Levofolic must be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If temperature excursions occur, discard the product according to local regulations.

Levofolic is administered by intravenous infusion. The healthcare professional selects the infusion rate and duration according to the clinical protocol, typically delivering the solution over several minutes to an hour, and monitors the patient for any immediate adverse reactions.

Serious risks include hypersensitivity reactions such as rash, bronchospasm or anaphylaxis, renal impairment especially in patients with pre‑existing kidney disease, and hematologic abnormalities like neutropenia or thrombocytopenia. Prompt medical evaluation is required if any of these events occur.

Levofolic should be avoided in individuals with known hypersensitivity to levoleucovorin or any component of the formulation, in patients with severe renal impairment unless dose‑adjusted by a specialist, and in those for whom the intended rescue or enhancement therapy is contraindicated.